^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FLT3-ITD mutation

    i
    Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
    Entrez ID:
    2322
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (NCT05554393)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    09/13/2024
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA
    |
    TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)
    Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene (NCT05886049)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/20/2024
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    FLT3 • NPM1 • KMT2A
    |
    FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation
    |
    daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)
    A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML (AGORA-1) (NCT05199051)
    Phase 2
    Centre Antoine Lacassagne
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    06/03/2023
    Primary completion :
    03/15/2027
    Completion :
    03/15/2027
    FLT3 • CD33
    |
    FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive
    |
    cytarabine • Xospata (gilteritinib) • Mylotarg (gemtuzumab ozogamicin)
    Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (NCT05457556)
    Phase 3
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/15/2023
    Primary completion :
    12/01/2027
    Completion :
    12/01/2027
    FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C
    |
    FLT3-ITD mutation
    |
    Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)
    ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCI-2021-06095) (NCT05010122)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/08/2021
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    FLT3
    |
    FLT3-ITD mutation • FLT3 mutation
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • Inqovi (decitabine/cedazuridine)
    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome (NCI-2018-01789) (NCT03661307)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/31/2018
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    TP53 • FLT3
    |
    TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion
    |
    Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib) • decitabine
    Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AAML1031) (NCT01371981)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/20/2011
    Primary completion :
    03/31/2019
    Completion :
    09/30/2027
    FLT3
    |
    FLT3-ITD mutation
    |
    sorafenib • cytarabine • bortezomib • etoposide IV • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
    Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients with Hematologic Malignancies (HTLP-ONCO) (NCT04707300)
    Phase 1/2
    Assistance Publique - Hôpitaux de Paris
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    02/16/2022
    Primary completion :
    11/01/2025
    Completion :
    08/01/2027
    HLA-DRB1 • CD34 • CD4 • CD7
    |
    FLT3-ITD mutation • NPM1 mutation
    |
    SMART 102
    A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML) (NCT04027309)
    Phase 3
    Stichting Hemato-Oncologie voor Volwassenen Ned...
    Active, not recruiting
    Last update posted :
    12/17/2024
    Initiation :
    12/20/2019
    Primary completion :
    10/01/2025
    Completion :
    06/01/2033
    FLT3
    |
    FLT3-ITD mutation • FLT3 mutation • FLT3-TKD mutation
    |
    Xospata (gilteritinib) • midostaurin
    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant (HBO-UBC) (NCT03739502)
    Phase 2
    University of Rochester
    Recruiting
    Last update posted :
    08/19/2024
    Initiation :
    02/28/2019
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A
    |
    FLT3-ITD mutation • NPM1 mutation
    Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML (NCT05024552)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    08/23/2021
    Primary completion :
    08/01/2024
    Completion :
    08/01/2025
    FLT3
    |
    FLT3-ITD mutation • FLT3-TKD mutation
    |
    Xospata (gilteritinib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. (NCT02310321)
    Phase 1/2
    Astellas Pharma Inc
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    02/26/2015
    Primary completion :
    08/25/2021
    Completion :
    07/31/2024
    FLT3
    |
    FLT3-ITD mutation
    |
    cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride